Overall survival after 177Lu-PSMA-617 molecular radiotherapy in patients with metastatic castrate-resistant prostate cancer: Post-hoc analysis of a prospective phase II trial.

Jeremie Calais,Jeannine Gartmann,Wesley R Armstrong,Pan Thin,Kathleen Nguyen,Vincent Lok,Laura Gosa,Roger Slavik,Magnus Dahlbom,Ken Herrmann,Matthias Eiber,Wolfgang P. Fendler,Johannes Czernin

Overall survival after 177Lu-PSMA-617 molecular radiotherapy in patients with metastatic castrate-resistant prostate cancer: Post-hoc analysis of a prospective phase II trial.

2020

Jeremie Calais
Jeannine Gartmann
Wesley R Armstrong
Pan Thin
Kathleen Nguyen
Vincent Lok
Laura Gosa
Roger Slavik
Magnus Dahlbom
Ken Herrmann
Matthias Eiber
Wolfgang P. Fendler
Johannes Czernin

5549Background: This was an open-label randomized prospective bi-centric single-arm phase II clinical trial of 177Lu-PSMA-617 molecular radiotherapy in patients with progressive metastatic castrate...

Keywords:

Castrate-resistant prostate cancer
Post-hoc analysis
Oncology
Internal medicine
overall survival
in patient
Pathology
177Lu-PSMA-617
Radiation therapy
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations